Cellectar Biosciences, Inc. — Form 10-Q summary
Reporting period: Three and six months ended June 30, 2014; filed August 4, 2014. Cellectar is a cancer-focused biopharmaceutical company developing imaging and therapeutic candidates. It reported no product revenue and remains focused on research and development.
Financial performance and position
| Metric | Q2 2014 | Six months 2014 | Comparable 2013 |
|---|---|---|---|
| Research and development expense | $1.381 million | $3.096 million | $3.239 million |
| General and administrative expense | $0.960 million | $2.047 million | $2.195 million |
| Restructuring expense | $0.205 million | $0.222 million | None reported |
| Net loss | $2.086 million | $5.029 million | $5.518 million |
| Basic and diluted loss per share | $0.73 | $1.75 | $2.03 |
| Cash used in operating activities | Not provided for the quarter | $4.602 million | $3.923 million |
Cash and cash equivalents were $1.626 million at June 30, down from $2.418 million at December 31, 2013. Total assets were $5.889 million and total liabilities were $8.429 million, leaving a stockholders’ deficit of $2.541 million. Current liabilities were $4.078 million versus current assets of $2.016 million. The company had $4.000 million principal amount of convertible debentures issued in February, bearing 8% interest and due February 2016; the reported carrying value was $3.797 million. It also had $2.841 million of warrant derivative liabilities. Gross margin is not meaningful because the filing reports no product revenue.
Changes and notable items
- Six-month net loss narrowed from $5.518 million to $5.029 million, primarily reflecting lower operating expenses and no 2013 loss on issuance of derivative warrants. Operating cash use increased by approximately $0.680 million.
- Six-month R&D expense declined 4.4%, while clinical project costs rose $281,000, mainly due to the Phase 2 I-124-CLR1404 glioblastoma study. Lower restructuring-related compensation, manufacturing, preclinical and equipment costs partly offset the increase.
- Six-month G&A expense decreased 6.7%. Restructuring costs included approximately $160,000 of severance payments to two employees following the Madison office consolidation.
- Derivative-warrant revaluation generated a non-cash gain of $519,000 in the first half, compared with $666,000 in 2013. The February 2013 offering warrants are valued using significant unobservable inputs.
- The company effected a 1-for-20 reverse stock split on June 13, 2014, reducing authorized common shares to 20 million. Share and per-share figures in the filing reflect the split.
Outlook, funding and risks
Management expects continuing operating losses and says cash at June 30, together with approximately $617,500 borrowed under secured notes on July 29, was expected to fund operations only through August 2014. Lenders could make an additional $382,500 available at their option. The notes bear 8% interest, mature 60 days after issuance or earlier upon a qualifying equity financing, and are secured by substantially all company assets; the convertible debentures share that security pari passu. Management said it was pursuing financing alternatives but had not entered negotiations and could not assure additional funding. Failure to raise capital could delay, scale back or end development programs.
Development plans included continuing I-124-CLR1404 trials, with the glioblastoma Phase 2 study expected to complete in the first half of 2015 subject to funding; pursuing multiple myeloma for I-131-CLR1404 and planning an IND submission in 2014; and anticipating an IND submission for preclinical CLR1502 in 2014. The FDA granted I-124-CLR1404 orphan status as a diagnostic for glioma in April 2014. These are management plans, not assured outcomes.
Other material risks include clinical and regulatory uncertainty, lack of product revenue, ongoing losses, financing and dilution risk, debt repayment and collateral constraints, and a pending appeal in the ZAO BAM dispute. Management did not expect that litigation to materially affect financial position, results or cash flows. The filing also says disclosure controls were effective as of June 30, 2014.
Important facts for investors to verify
- Whether additional financing was obtained after the July 2014 secured-note closing and whether funding extended beyond the stated August runway.
- Cash burn, the status and repayment or conversion terms of the 8% debentures and secured notes, and any impact of liens on substantially all assets.
- Progress, funding and regulatory status of the I-124-CLR1404, I-131-CLR1404 and CLR1502 programs, including the stated 2014 IND plans and 2015 trial milestone.
- Potential dilution from outstanding warrants, options and convertible debt; the filing lists 1,964,085 warrant shares and 619,663 option shares outstanding at June 30.
- Developments in the ZAO BAM appeal and any resulting financial or intellectual-property exposure.